1 / 1

Online Resource 1. Characteristics of patients.

Online Resource 1. Characteristics of patients. No. of patients % Age <60 39 48.8 ≥60 41 51.1 Histology DCIS 2 2.5

jamese
Download Presentation

Online Resource 1. Characteristics of patients.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Online Resource 1. Characteristics of patients. • No. of patients % • Age • <60 39 48.8 • ≥60 41 51.1 • Histology • DCIS 2 2.5 • IDC 70 87.5 • Others 8 10.0 • Stage • 0 2 2.5 • I 22 27.5 • II 38 47.5 • III 8 10.0 • IV 10 12.5 • Grade • 12 15.0 • 2 42 52.5 • 3 19 23.8 • Unknown 7 8.7 • Node • Positive 25 31.2 • Negative 47 58.8 • Unknown 8 10.0 No. of patients % ER Positive 54 67.5 Negative 21 26.3 Unknown 5 6.2 HER2 Positive 14 17.5 Negative 61 76.3 Unknown 5 6.2 Ki67 ≥30% 16 20.0 14%–30% 23 28.8 <14% 34 42.5 Unknown 7 8.7 Subtype Luminal A 28 35.0 Luminal B 16 20.0 Luminal–HER2 8 10.0 HER2 6 7.5 Triple negative 15 18.8 Unknown 7 8.7 Tumor biopsy samples were examined by staining with a standard panel of immunohistochemistry markers, ER, PR(progesteron receptor), HER2, and Ki67. The definition of each tumor subtype determined by means of using the standard markers is as follows; luminal A: ER+ and/or PR+, HER2-, Ki67<14%; luminal B: ER+ and/or PR+, HER2-, Ki67≥14%; luminal-HER2: ER+ and/or PR+, HER2+; HER2: ER- , PR-, HER2+ ; triple negative: ER- , PR-, HER2- .

More Related